T. Rowe Price Investment Management, Inc. Novo Cure LTD Transaction History

T. Rowe Price Investment Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$14.54 - $33.41 $16.2 Million - $37.3 Million	-1,115,692 Reduced 39.76%	1,690,441 $50.4 Million
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $17.1 Million - $25.5 Million	1,093,740 Added 63.87%	2,806,133 $43.9 Million
Q2 2024 Aug 14, 2024	BUY	$11.83 - $24.05 $20.3 Million - $41.2 Million	1,712,393 New	1,712,393 $29.3 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $12.6 Million - $25.8 Million	312,351 Added 19.79%	1,890,836 $78.5 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $86.5 Million - $182 Million	1,533,426 Added 3403.15%	1,578,485 $94.9 Million
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $2.88 Million - $3.85 Million	45,059 New	45,059 $3.31 Million

265

80.5M

970K

118K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.19B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.